Eli LillyLLY
About: Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
Employees: 43,000
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
54% more first-time investments, than exits
New positions opened: 269 | Existing positions closed: 175
21% more funds holding in top 10
Funds holding in top 10: 448 [Q1] → 540 (+92) [Q2]
16% more capital invested
Capital invested by funds: $608B [Q1] → $706B (+$98.3B) [Q2]
14% more repeat investments, than reductions
Existing positions increased: 1,483 | Existing positions reduced: 1,301
11.16% more ownership
Funds ownership: 70.97% [Q1] → 82.13% (+11.16%) [Q2]
3% more funds holding
Funds holding: 3,379 [Q1] → 3,473 (+94) [Q2]
18% less call options, than puts
Call options by funds: $8.06B | Put options by funds: $9.87B
Research analyst outlook
18 Wall Street Analysts provided 1 year price targets over the past 3 months
18 analyst ratings
Bernstein | 21%upside $1,100 | Outperform Initiated | 17 Oct 2024 |
Truist Securities Srikripa Devarakonda 64% 1-year accuracy 14 / 22 met price target | 14%upside $1,033 | Buy Maintained | 10 Oct 2024 |
Deutsche Bank James Shin 67% 1-year accuracy 4 / 6 met price target | 13%upside $1,025 | Buy Reiterated | 3 Oct 2024 |
Cantor Fitzgerald Louise Chen 56% 1-year accuracy 69 / 124 met price target | 2%downside $885 | Overweight Reiterated | 16 Sept 2024 |
JP Morgan Chris Schott 33% 1-year accuracy 3 / 9 met price target | 21%upside $1,100 | Overweight Maintained | 13 Sept 2024 |
Financial journalist opinion
Based on 93 articles about LLY published over the past 30 days
